Kien-Ninh Ina Ly, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurofibromatosis 1 | 8 | 2023 | 569 | 2.410 |
Why?
|
| Neurofibroma | 3 | 2023 | 106 | 1.880 |
Why?
|
| Neurofibroma, Plexiform | 3 | 2022 | 71 | 1.230 |
Why?
|
| Neurofibromatoses | 4 | 2022 | 299 | 0.880 |
Why?
|
| Neurilemmoma | 4 | 2022 | 547 | 0.790 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2019 | 895 | 0.770 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 45 | 0.640 |
Why?
|
| Skin Neoplasms | 6 | 2023 | 5686 | 0.580 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2018 | 290 | 0.490 |
Why?
|
| Perceptual Disorders | 1 | 2015 | 196 | 0.470 |
Why?
|
| World Health Organization | 1 | 2019 | 1318 | 0.460 |
Why?
|
| Patient Care | 1 | 2018 | 640 | 0.420 |
Why?
|
| Brain Neoplasms | 4 | 2019 | 8863 | 0.380 |
Why?
|
| Visual Fields | 1 | 2015 | 1047 | 0.330 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 1855 | 0.310 |
Why?
|
| Genetic Testing | 2 | 2022 | 3444 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2022 | 35421 | 0.300 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2737 | 0.290 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 3586 | 0.280 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 2038 | 0.260 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 3507 | 0.230 |
Why?
|
| Glioma | 4 | 2019 | 3401 | 0.230 |
Why?
|
| Glioblastoma | 1 | 2018 | 3481 | 0.230 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2011 | 1052 | 0.200 |
Why?
|
| Arthrogryposis | 1 | 2022 | 72 | 0.200 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2022 | 190 | 0.190 |
Why?
|
| Pruritus | 1 | 2023 | 361 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2022 | 8949 | 0.170 |
Why?
|
| Neurofibromatosis 2 | 1 | 2022 | 380 | 0.160 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 13695 | 0.160 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2017 | 91 | 0.150 |
Why?
|
| Glutarates | 1 | 2018 | 236 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 648 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 627 | 0.120 |
Why?
|
| Visual Field Tests | 1 | 2015 | 383 | 0.110 |
Why?
|
| Quality of Life | 3 | 2023 | 12804 | 0.110 |
Why?
|
| Radiometry | 1 | 2018 | 800 | 0.110 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 871 | 0.110 |
Why?
|
| Brain Edema | 1 | 2017 | 617 | 0.100 |
Why?
|
| Humans | 20 | 2023 | 744343 | 0.100 |
Why?
|
| Osteoarthritis, Knee | 1 | 2022 | 1222 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3479 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 2513 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 2765 | 0.090 |
Why?
|
| Neoplasms | 1 | 2018 | 21683 | 0.090 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2009 | 43 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 39050 | 0.080 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2009 | 170 | 0.080 |
Why?
|
| Adult | 7 | 2023 | 214055 | 0.080 |
Why?
|
| Antigenic Variation | 1 | 2009 | 125 | 0.080 |
Why?
|
| Regeneration | 1 | 2017 | 1485 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2459 | 0.080 |
Why?
|
| Middle Aged | 7 | 2022 | 213383 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2018 | 3760 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 3798 | 0.070 |
Why?
|
| Meningioma | 1 | 2015 | 1209 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 1241 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2022 | 53288 | 0.070 |
Why?
|
| Young Adult | 3 | 2022 | 56430 | 0.070 |
Why?
|
| Aged | 4 | 2022 | 163280 | 0.070 |
Why?
|
| Contrast Media | 1 | 2018 | 5300 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2022 | 1915 | 0.060 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2009 | 594 | 0.060 |
Why?
|
| Survival Rate | 1 | 2018 | 12788 | 0.060 |
Why?
|
| Child | 3 | 2022 | 77709 | 0.060 |
Why?
|
| Adolescent | 3 | 2022 | 85781 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 12959 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 11031 | 0.060 |
Why?
|
| Spinal Cord | 1 | 2011 | 1809 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 6234 | 0.050 |
Why?
|
| Male | 7 | 2021 | 350118 | 0.050 |
Why?
|
| Prognosis | 2 | 2019 | 29063 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 9239 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2009 | 1888 | 0.040 |
Why?
|
| Algorithms | 1 | 2019 | 13881 | 0.040 |
Why?
|
| Biopsy | 1 | 2011 | 6756 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2009 | 3494 | 0.040 |
Why?
|
| Photography | 1 | 2021 | 520 | 0.040 |
Why?
|
| Mutation | 2 | 2019 | 29786 | 0.040 |
Why?
|
| Brain | 2 | 2017 | 26385 | 0.040 |
Why?
|
| Automation | 1 | 2019 | 584 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2018 | 41006 | 0.030 |
Why?
|
| Analgesics | 1 | 2022 | 1040 | 0.030 |
Why?
|
| Female | 4 | 2018 | 380194 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2022 | 77449 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57776 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2019 | 1486 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2022 | 3420 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2282 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 956 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2022 | 10943 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4933 | 0.020 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 1 | 2009 | 9 | 0.020 |
Why?
|
| Animals | 3 | 2017 | 168757 | 0.020 |
Why?
|
| Gene Conversion | 1 | 2009 | 71 | 0.020 |
Why?
|
| Sequence Analysis | 1 | 2009 | 256 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2022 | 12026 | 0.020 |
Why?
|
| Monocytes | 1 | 2017 | 2596 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5535 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 7913 | 0.020 |
Why?
|
| Gene Expression | 1 | 2018 | 7799 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 4042 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13989 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 19905 | 0.010 |
Why?
|
| Macrophages | 1 | 2017 | 5655 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14557 | 0.010 |
Why?
|
| DNA Replication | 1 | 2009 | 1399 | 0.010 |
Why?
|
| DNA Repair | 1 | 2009 | 2046 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6171 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 18029 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2009 | 2752 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2022 | 63114 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 81183 | 0.010 |
Why?
|